<?xml version="1.0" encoding="UTF-8"?>
<!-- This sitemap was dynamically generated on November 17, 2026 at 11:40 pm by All in One SEO v5.0.5.1 - the original SEO plugin for WordPress. -->

<?xml-stylesheet type="text/xsl" href="https://helixgatebiotechreview.com/default-sitemap.xsl"?>

<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
	<channel>
		<title>Helixgate</title>
		<link><![CDATA[https://helixgatebiotechreview.com]]></link>
		<description><![CDATA[Helixgate]]></description>
		<lastBuildDate><![CDATA[Tue, 17 Nov 2026 23:11:11 +0000]]></lastBuildDate>
		<docs>https://validator.w3.org/feed/docs/rss2.html</docs>
		<atom:link href="https://helixgatebiotechreview.com/sitemap.rss" rel="self" type="application/rss+xml" />
		<ttl><![CDATA[60]]></ttl>

		<item>
			<guid><![CDATA[https://www.labiotech.eu/top-pharma-strategy/regeneron-pipeline-2027/]]></guid>
			<link><![CDATA[https://www.labiotech.eu/top-pharma-strategy/regeneron-pipeline-2027/]]></link>
			<title>Where is Regeneron headed after record third quarter? </title>
			<pubDate><![CDATA[Tue, 17 Nov 2026 23:11:11 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.statnews.com/pharmalot/2026/11/17/roche-breast-cancer-pill-obesity-drugs-in-children/?utm_campaign=rss]]></guid>
			<link><![CDATA[https://www.statnews.com/pharmalot/2026/11/17/roche-breast-cancer-pill-obesity-drugs-in-children/?utm_campaign=rss]]></link>
			<title>STAT+: Pharmalittle: We’re reading about a Roche breast cancer pill, obesity drugs in children, and more</title>
			<pubDate><![CDATA[Tue, 17 Nov 2026 22:39:34 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.statnews.com/2026/11/17/biotech-news-flagship-opens-biotech-creation-uk-outpost/?utm_campaign=rss]]></guid>
			<link><![CDATA[https://www.statnews.com/2026/11/17/biotech-news-flagship-opens-biotech-creation-uk-outpost/?utm_campaign=rss]]></link>
			<title>STAT+: Flagship opens biotech-creation outpost in the U.K.</title>
			<pubDate><![CDATA[Tue, 17 Nov 2026 22:39:33 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.biospace.com/drug-development/sellas-cancer-vaccine-slashes-death-risk-by-41-in-late-stage-aml-study]]></guid>
			<link><![CDATA[https://www.biospace.com/drug-development/sellas-cancer-vaccine-slashes-death-risk-by-41-in-late-stage-aml-study]]></link>
			<title>Sellas’ cancer vaccine slashes death risk by 41% in late-stage AML study</title>
			<pubDate><![CDATA[Tue, 17 Nov 2026 21:17:41 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.biospace.com/fda/vertex-on-the-verge-of-iconic-evolution-as-key-kidney-disease-verdict-looms]]></guid>
			<link><![CDATA[https://www.biospace.com/fda/vertex-on-the-verge-of-iconic-evolution-as-key-kidney-disease-verdict-looms]]></link>
			<title>Vertex on the verge of ‘iconic’ evolution as key kidney disease verdict looms</title>
			<pubDate><![CDATA[Tue, 17 Nov 2026 21:17:39 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://bioengineer.org/plasma-protein-panel-distinguishes-parkinsons-disease-from-healthy-controls-in-study/]]></guid>
			<link><![CDATA[https://bioengineer.org/plasma-protein-panel-distinguishes-parkinsons-disease-from-healthy-controls-in-study/]]></link>
			<title>Plasma Protein Panel Distinguishes Parkinson’s Disease From Healthy Controls in Study</title>
			<pubDate><![CDATA[Tue, 17 Nov 2026 20:49:55 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://bioengineer.org/moringa-leaf-silver-nanoparticles-inhibit-drug-resistant-hospital-pathogens-in-lab-tests/]]></guid>
			<link><![CDATA[https://bioengineer.org/moringa-leaf-silver-nanoparticles-inhibit-drug-resistant-hospital-pathogens-in-lab-tests/]]></link>
			<title>Moringa Leaf Silver Nanoparticles Inhibit Drug-Resistant Hospital Pathogens in Lab Tests</title>
			<pubDate><![CDATA[Tue, 17 Nov 2026 20:49:25 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://pharmaphorum.com/news/helus-shares-slide-psychedelic-readout-depression]]></guid>
			<link><![CDATA[https://pharmaphorum.com/news/helus-shares-slide-psychedelic-readout-depression]]></link>
			<title>Helus shares slide on psychedelic readout in depression</title>
			<pubDate><![CDATA[Tue, 17 Nov 2026 20:07:04 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://pharmaphorum.com/news/uk-sets-2029-timeline-end-palantirs-nhs-contract]]></guid>
			<link><![CDATA[https://pharmaphorum.com/news/uk-sets-2029-timeline-end-palantirs-nhs-contract]]></link>
			<title>UK sets 2029 timeline to end Palantir&#8217;s NHS contract</title>
			<pubDate><![CDATA[Tue, 17 Nov 2026 20:07:02 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://pharmaphorum.com/news/roche-joins-oral-serd-club-fda-clears-wilserdly]]></guid>
			<link><![CDATA[https://pharmaphorum.com/news/roche-joins-oral-serd-club-fda-clears-wilserdly]]></link>
			<title>Roche joins the oral SERD club as FDA clears Wilserdly</title>
			<pubDate><![CDATA[Tue, 17 Nov 2026 20:07:01 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://pharmaphorum.com/news/isomorphic-labs-raises-5bn-massive-third-round]]></guid>
			<link><![CDATA[https://pharmaphorum.com/news/isomorphic-labs-raises-5bn-massive-third-round]]></link>
			<title>Isomorphic Labs raises $5bn in massive third round</title>
			<pubDate><![CDATA[Tue, 17 Nov 2026 20:07:00 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.drugs.com/clinical_trials/amylyx-pharmaceuticals-presents-results-phase-3-lucidity-clinical-trial-avexitide-post-bariatric-22687.html]]></guid>
			<link><![CDATA[https://www.drugs.com/clinical_trials/amylyx-pharmaceuticals-presents-results-phase-3-lucidity-clinical-trial-avexitide-post-bariatric-22687.html]]></link>
			<title>Amylyx Pharmaceuticals Presents Results from Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia</title>
			<pubDate><![CDATA[Tue, 17 Nov 2026 18:23:27 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.drugs.com/clinical_trials/wegovy-resulted-bmi-reduction-10-more-almost-80-children-obesity-aged-6-under-12-compared-0-placebo-22686.html]]></guid>
			<link><![CDATA[https://www.drugs.com/clinical_trials/wegovy-resulted-bmi-reduction-10-more-almost-80-children-obesity-aged-6-under-12-compared-0-placebo-22686.html]]></link>
			<title>Wegovy Resulted in a BMI Reduction of 10% or More in Almost 80% of Children with Obesity Aged 6 to Under 12, Compared to 0% with Placebo in STEP Young Trial, Published in The New England Journal of Medicine</title>
			<pubDate><![CDATA[Tue, 17 Nov 2026 18:23:26 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.drugs.com/clinical_trials/novo-s-cagrisema-associated-25-mean-weight-loss-among-early-responders-post-hoc-analysis-redefine-1-22685.html]]></guid>
			<link><![CDATA[https://www.drugs.com/clinical_trials/novo-s-cagrisema-associated-25-mean-weight-loss-among-early-responders-post-hoc-analysis-redefine-1-22685.html]]></link>
			<title>Novo&#8217;s CagriSema was Associated with 25% Mean Weight Loss Among Early Responders in a Post Hoc Analysis of REDEFINE 1</title>
			<pubDate><![CDATA[Tue, 17 Nov 2026 18:23:26 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[http://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/island-kinetics-inc-dba-covalence-laboratories-726379-07162026]]></guid>
			<link><![CDATA[http://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/island-kinetics-inc-dba-covalence-laboratories-726379-07162026]]></link>
			<title>Island Kinetics, Inc. d.b.a. CoValence Laboratories &#8211; 726379 &#8211; 07/16/2026</title>
			<pubDate><![CDATA[Tue, 17 Nov 2026 17:01:13 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[http://www.fda.gov/drugs/human-drug-compounding/registered-outsourcing-facilities]]></guid>
			<link><![CDATA[http://www.fda.gov/drugs/human-drug-compounding/registered-outsourcing-facilities]]></link>
			<title>Registered Outsourcing Facilities</title>
			<pubDate><![CDATA[Tue, 17 Nov 2026 15:33:06 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.biocentury.com/article/661602/sofinnova-partners-goes-bigger-with-725m-crossover-ii-fund?utm_source=bc_rss&amp;utm_medium=rss]]></guid>
			<link><![CDATA[https://www.biocentury.com/article/661602/sofinnova-partners-goes-bigger-with-725m-crossover-ii-fund?utm_source=bc_rss&amp;utm_medium=rss]]></link>
			<title>Sofinnova Partners goes bigger with €725M Crossover II fund</title>
			<pubDate><![CDATA[Tue, 17 Nov 2026 13:03:00 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.biocentury.com/article/661623/lexeo-plans-pivotal-gene-therapy-trial-aimed-at-accelerated-approval?utm_source=bc_rss&amp;utm_medium=rss]]></guid>
			<link><![CDATA[https://www.biocentury.com/article/661623/lexeo-plans-pivotal-gene-therapy-trial-aimed-at-accelerated-approval?utm_source=bc_rss&amp;utm_medium=rss]]></link>
			<title>Lexeo plans pivotal gene therapy trial aimed at accelerated approval</title>
			<pubDate><![CDATA[Tue, 17 Nov 2026 13:02:50 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.biocentury.com/article/661498/rare-disease-spotlight-attacking-the-same-bleeding-problem-from-four-directions?utm_source=bc_rss&amp;utm_medium=rss]]></guid>
			<link><![CDATA[https://www.biocentury.com/article/661498/rare-disease-spotlight-attacking-the-same-bleeding-problem-from-four-directions?utm_source=bc_rss&amp;utm_medium=rss]]></link>
			<title>Rare Disease Spotlight: Attacking the same bleeding problem from four directions</title>
			<pubDate><![CDATA[Tue, 17 Nov 2026 13:02:46 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.biocentury.com/article/661621/after-gene-therapy-setbacks-j-j-pays-2-2b-for-ollin-adds-retinal-disease-candidate?utm_source=bc_rss&amp;utm_medium=rss]]></guid>
			<link><![CDATA[https://www.biocentury.com/article/661621/after-gene-therapy-setbacks-j-j-pays-2-2b-for-ollin-adds-retinal-disease-candidate?utm_source=bc_rss&amp;utm_medium=rss]]></link>
			<title>After gene therapy setbacks, J&amp;J  pays $2.2B for Ollin, adds retinal disease candidate</title>
			<pubDate><![CDATA[Tue, 17 Nov 2026 13:02:37 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.biocentury.com/article/661634/fda-holds-summit-to-survival-bar-in-ivonescimab-crl?utm_source=bc_rss&amp;utm_medium=rss]]></guid>
			<link><![CDATA[https://www.biocentury.com/article/661634/fda-holds-summit-to-survival-bar-in-ivonescimab-crl?utm_source=bc_rss&amp;utm_medium=rss]]></link>
			<title>FDA holds Summit to survival bar in ivonescimab CRL</title>
			<pubDate><![CDATA[Tue, 17 Nov 2026 13:02:27 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[http://www.fda.gov/drugs/drug-approvals-and-databases/drugsfda-data-files]]></guid>
			<link><![CDATA[http://www.fda.gov/drugs/drug-approvals-and-databases/drugsfda-data-files]]></link>
			<title>Drugs@FDA Data Files</title>
			<pubDate><![CDATA[Tue, 17 Nov 2026 12:42:45 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.genengnews.com/topics/genome-editing/single-cell-method-reveals-on-and-off-target-effects-of-cas9-edits-on-gene-expression/]]></guid>
			<link><![CDATA[https://www.genengnews.com/topics/genome-editing/single-cell-method-reveals-on-and-off-target-effects-of-cas9-edits-on-gene-expression/]]></link>
			<title>Single-Cell Method Reveals On- and Off-Target Effects of Cas9 Edits on Gene Expression</title>
			<pubDate><![CDATA[Tue, 17 Nov 2026 09:34:03 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.genengnews.com/topics/toward-connected-laboratory-ecosystems/]]></guid>
			<link><![CDATA[https://www.genengnews.com/topics/toward-connected-laboratory-ecosystems/]]></link>
			<title>Toward Connected Laboratory Ecosystems</title>
			<pubDate><![CDATA[Tue, 17 Nov 2026 09:33:59 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.genengnews.com/topics/translational-medicine/enhancer-targeted-crispr-turns-up-healthy-gene-copy-in-autism-organoid-model/]]></guid>
			<link><![CDATA[https://www.genengnews.com/topics/translational-medicine/enhancer-targeted-crispr-turns-up-healthy-gene-copy-in-autism-organoid-model/]]></link>
			<title>Enhancer-Targeted CRISPR Turns Up Healthy Gene Copy in Autism Organoid Model</title>
			<pubDate><![CDATA[Tue, 17 Nov 2026 09:33:58 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.statnews.com/2026/11/16/fda-approves-new-roche-breast-cancer-drug/?utm_campaign=rss]]></guid>
			<link><![CDATA[https://www.statnews.com/2026/11/16/fda-approves-new-roche-breast-cancer-drug/?utm_campaign=rss]]></link>
			<title>STAT+: FDA approves new breast cancer drug, providing new option for some patients, boost for Roche</title>
			<pubDate><![CDATA[Tue, 17 Nov 2026 05:39:59 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.pharmavoice.com/news/china-pharma-global-expansion-us-commercialization/874673/]]></guid>
			<link><![CDATA[https://www.pharmavoice.com/news/china-pharma-global-expansion-us-commercialization/874673/]]></link>
			<title>China’s pharma industry wants to go global. The US could get in its way.</title>
			<pubDate><![CDATA[Tue, 17 Nov 2026 04:41:25 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.biopharmadive.com/news/sofinnova-crossover-fund-ii-european-investment/874656/]]></guid>
			<link><![CDATA[https://www.biopharmadive.com/news/sofinnova-crossover-fund-ii-european-investment/874656/]]></link>
			<title>One of Europe’s leading VCs banks a €725M ‘crossover’ fund</title>
			<pubDate><![CDATA[Tue, 17 Nov 2026 02:07:02 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.biopharmadive.com/news/seawolf-therapeutics-dna-versant-startup-financing/874465/]]></guid>
			<link><![CDATA[https://www.biopharmadive.com/news/seawolf-therapeutics-dna-versant-startup-financing/874465/]]></link>
			<title>Big-name investors pour $100M into DNA therapeutics developer Seawolf</title>
			<pubDate><![CDATA[Tue, 17 Nov 2026 02:07:01 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.biopharmadive.com/spons/the-infrastructure-decisions-that-will-enable-tomorrows-biggest-breakthrou/874507/]]></guid>
			<link><![CDATA[https://www.biopharmadive.com/spons/the-infrastructure-decisions-that-will-enable-tomorrows-biggest-breakthrou/874507/]]></link>
			<title>The infrastructure decisions that will enable tomorrow’s biggest breakthroughs</title>
			<pubDate><![CDATA[Tue, 17 Nov 2026 02:06:58 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.biopharmadive.com/news/lilly-calytrix-bio-acquire-deal-myelofibrosis-essential-thrombocythemiaenial-/874719/]]></guid>
			<link><![CDATA[https://www.biopharmadive.com/news/lilly-calytrix-bio-acquire-deal-myelofibrosis-essential-thrombocythemiaenial-/874719/]]></link>
			<title>Lilly adds to buyout streak with $1.5B purchase of startup Calytrix</title>
			<pubDate><![CDATA[Tue, 17 Nov 2026 02:06:57 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.biopharmadive.com/news/Johnson-johnson-ollin-acquire-ophthalmology-vegf-ang2-drugs/874728/]]></guid>
			<link><![CDATA[https://www.biopharmadive.com/news/Johnson-johnson-ollin-acquire-ophthalmology-vegf-ang2-drugs/874728/]]></link>
			<title>J&amp;J bets $2.2B on Ollin’s vision loss drug</title>
			<pubDate><![CDATA[Tue, 17 Nov 2026 02:06:56 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.biopharmadive.com/news/summit-akeso-fda-ivonescimab-reject-egfr-lung-cancer/874745/]]></guid>
			<link><![CDATA[https://www.biopharmadive.com/news/summit-akeso-fda-ivonescimab-reject-egfr-lung-cancer/874745/]]></link>
			<title>Summit shares fall as FDA rejects closely watched PD-1/VEGF drug</title>
			<pubDate><![CDATA[Tue, 17 Nov 2026 02:06:55 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.biospace.com/business/biospace-40-under-40-winners-paull-zhang-let-patients-with-rare-disease-lead-the-way-at-bridgebio]]></guid>
			<link><![CDATA[https://www.biospace.com/business/biospace-40-under-40-winners-paull-zhang-let-patients-with-rare-disease-lead-the-way-at-bridgebio]]></link>
			<title>BioSpace 40 Under 40 winners Paull, Zhang let patients with rare disease lead the way at BridgeBio</title>
			<pubDate><![CDATA[Tue, 17 Nov 2026 00:12:19 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.biospace.com/drug-development/opinion-emerging-biotech-hubs-step-up-as-innovation-economics-evolve]]></guid>
			<link><![CDATA[https://www.biospace.com/drug-development/opinion-emerging-biotech-hubs-step-up-as-innovation-economics-evolve]]></link>
			<title>Emerging biotech hubs step up as innovation economics evolve</title>
			<pubDate><![CDATA[Tue, 17 Nov 2026 00:12:17 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.biospace.com/business/their-loss-our-gain-canada-makes-its-case-to-europe-amid-u-s-instability]]></guid>
			<link><![CDATA[https://www.biospace.com/business/their-loss-our-gain-canada-makes-its-case-to-europe-amid-u-s-instability]]></link>
			<title>Their loss, our gain? Canada makes its case to Europe amid U.S. instability</title>
			<pubDate><![CDATA[Tue, 17 Nov 2026 00:12:10 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.biospace.com/drug-development/novos-cagrisema-drives-more-than-20-weight-loss-at-lower-doses]]></guid>
			<link><![CDATA[https://www.biospace.com/drug-development/novos-cagrisema-drives-more-than-20-weight-loss-at-lower-doses]]></link>
			<title>Novo’s CagriSema drives more than 20% weight loss at lower doses</title>
			<pubDate><![CDATA[Tue, 17 Nov 2026 00:12:08 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.biospace.com/drug-development/fdas-summit-rejection-puts-pd-1xvegf-class-on-notice-to-establish-overall-survival]]></guid>
			<link><![CDATA[https://www.biospace.com/drug-development/fdas-summit-rejection-puts-pd-1xvegf-class-on-notice-to-establish-overall-survival]]></link>
			<title>FDA’s Summit rejection puts PD-1xVEGF class on notice to establish overall survival</title>
			<pubDate><![CDATA[Tue, 17 Nov 2026 00:12:06 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.biospace.com/deals/j-j-pays-2-2b-upfront-for-ollin-taps-blackstone-to-fund-eye-disease-trial]]></guid>
			<link><![CDATA[https://www.biospace.com/deals/j-j-pays-2-2b-upfront-for-ollin-taps-blackstone-to-fund-eye-disease-trial]]></link>
			<title>J&amp;J pays $2.2B upfront for Ollin, taps Blackstone to fund eye disease trial</title>
			<pubDate><![CDATA[Tue, 17 Nov 2026 00:12:05 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.biospace.com/drug-development/serious-adverse-events-mar-robust-efficacy-data-for-helus-psychedelic-in-major-depression]]></guid>
			<link><![CDATA[https://www.biospace.com/drug-development/serious-adverse-events-mar-robust-efficacy-data-for-helus-psychedelic-in-major-depression]]></link>
			<title>Serious adverse events mar robust efficacy data for Helus’ psychedelic in major depression</title>
			<pubDate><![CDATA[Tue, 17 Nov 2026 00:12:02 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.biospace.com/drug-development/serious-adverse-events-mar-robust-efficacy-data-for-helus-psychedelic-in-major-depression]]></guid>
			<link><![CDATA[https://www.biospace.com/drug-development/serious-adverse-events-mar-robust-efficacy-data-for-helus-psychedelic-in-major-depression]]></link>
			<title>Serious adverse events mar robust efficacy data for Helus’ psychedelic in major depression</title>
			<pubDate><![CDATA[Tue, 17 Nov 2026 00:12:01 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.statnews.com/2026/11/16/fda-proposes-new-category-supplement-nac/?utm_campaign=rss]]></guid>
			<link><![CDATA[https://www.statnews.com/2026/11/16/fda-proposes-new-category-supplement-nac/?utm_campaign=rss]]></link>
			<title>STAT+: In a win for MAHA, FDA creates new regulatory category for the supplement NAC</title>
			<pubDate><![CDATA[Mon, 16 Nov 2026 22:24:24 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.statnews.com/2026/11/15/fda-rejects-ivonescimab-lung-cancer-treatment-summit-therapeutics/?utm_campaign=rss]]></guid>
			<link><![CDATA[https://www.statnews.com/2026/11/15/fda-rejects-ivonescimab-lung-cancer-treatment-summit-therapeutics/?utm_campaign=rss]]></link>
			<title>STAT+: FDA rejects lung cancer treatment ivonescimab from Summit Therapeutics</title>
			<pubDate><![CDATA[Mon, 16 Nov 2026 21:48:00 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.statnews.com/2026/11/16/beone-hengrui-top-list-of-chinas-most-powerful-drugmakers/?utm_campaign=rss]]></guid>
			<link><![CDATA[https://www.statnews.com/2026/11/16/beone-hengrui-top-list-of-chinas-most-powerful-drugmakers/?utm_campaign=rss]]></link>
			<title>BeOne, Hengrui top list of China’s most powerful drugmakers</title>
			<pubDate><![CDATA[Mon, 16 Nov 2026 21:47:59 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.statnews.com/2026/11/16/versant-lilly-put-100-million-behind-new-startup-aimed-at-solving-one-of-gene-therapys-thorniest-issues/?utm_campaign=rss]]></guid>
			<link><![CDATA[https://www.statnews.com/2026/11/16/versant-lilly-put-100-million-behind-new-startup-aimed-at-solving-one-of-gene-therapys-thorniest-issues/?utm_campaign=rss]]></link>
			<title>STAT+: Versant, Lilly put $100 million behind new startup aimed at solving one of gene therapy’s thorniest issues</title>
			<pubDate><![CDATA[Mon, 16 Nov 2026 21:47:58 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.statnews.com/2026/11/16/bladder-cancer-immunotherapy-reduced-tumor-recurrence-cg-oncology/?utm_campaign=rss]]></guid>
			<link><![CDATA[https://www.statnews.com/2026/11/16/bladder-cancer-immunotherapy-reduced-tumor-recurrence-cg-oncology/?utm_campaign=rss]]></link>
			<title>STAT+: Bladder cancer immunotherapy from CG Oncology reduced risk of tumor recurrence</title>
			<pubDate><![CDATA[Mon, 16 Nov 2026 21:47:57 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.statnews.com/2026/11/16/helus-psychedelics-depression-phase-3-trial/?utm_campaign=rss]]></guid>
			<link><![CDATA[https://www.statnews.com/2026/11/16/helus-psychedelics-depression-phase-3-trial/?utm_campaign=rss]]></link>
			<title>STAT+: Helus’ psychedelic drug improved depression in study but faces safety questions</title>
			<pubDate><![CDATA[Mon, 16 Nov 2026 21:47:56 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.statnews.com/pharmalot/2026/11/16/glp1-use-covid-19-vaccines-return-on-investment/?utm_campaign=rss]]></guid>
			<link><![CDATA[https://www.statnews.com/pharmalot/2026/11/16/glp1-use-covid-19-vaccines-return-on-investment/?utm_campaign=rss]]></link>
			<title>STAT+: Pharmalittle: We’re reading about GLP-1 use, Covid-19 vaccine investment returns, and more</title>
			<pubDate><![CDATA[Mon, 16 Nov 2026 21:37:36 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.statnews.com/2026/11/16/biotech-news-rebound-isnt-lifting-all-boats-equally/?utm_campaign=rss]]></guid>
			<link><![CDATA[https://www.statnews.com/2026/11/16/biotech-news-rebound-isnt-lifting-all-boats-equally/?utm_campaign=rss]]></link>
			<title>STAT+: Biotech’s rebound isn’t lifting all boats equally</title>
			<pubDate><![CDATA[Mon, 16 Nov 2026 21:37:35 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://helixgatebiotechreview.com/]]></guid>
			<link><![CDATA[https://helixgatebiotechreview.com/]]></link>
			<title>Home</title>
			<pubDate><![CDATA[Mon, 07 Sep 2026 03:39:54 +0000]]></pubDate>
		</item>
				</channel>
</rss>
